Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun;14(6):1753-1757.
doi: 10.21037/jtd-22-364.

Diagnosis and treatment of non-small cell lung cancer: current advances and challenges

Ian Diebels  1 , Paul E Y Van Schil  1
Affiliations
Editorial

Diagnosis and treatment of non-small cell lung cancer: current advances and challenges

Ian Diebels et al. J Thorac Dis. 2022 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-364/coif). PEYVS reports institutional fees from AstraZeneca, MSD and Roche. PEYVS is also the unpaid Treasurer of Belgian Association for Cardiothoracic Surgery and unpaid President-elect of International Association for the Study of Lung Cancer. The other author has no conflicts of interest to declare.

Comment on

References

    1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. 10.1056/NEJMoa011954 - DOI - PubMed
    1. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018;36:911-9. 10.1200/JCO.2017.76.7293 - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Yoshioka H, Shimokawa M, Seto T, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol 2019;30:1978-84. 10.1093/annonc/mdz399 - DOI - PubMed
    1. Zhou C, Yao LD. Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature. J Thorac Oncol 2016;11:174-86. Erratum in: J Thorac Oncol 2016;11:776. 10.1016/j.jtho.2015.10.002 - DOI - PubMed